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ENDOCRINOLOGY AND WOMEN’S
SPORTS: THE DIAGNOSIS MATTERS
RICHARD J. AUCHUS*
INTRODUCTION
The participation of women in sports, and in particular elite sports, is a
relatively recent phenomenon starting at the turn of the twentieth century.
Shortly after the establishment of women’s competitions in the Olympic Games,
a few participants who were later found to be biologically male competed in these
events.1 These instances led to efforts to police the entry criteria to the women’s
events, but sport authorities soon recognized that a single dichotomous criterion
for defining a “female” athlete was difficult to identify.
In parallel with the rise of women’s sports, doping with performanceenhancing substances, particularly androgens, began to plague elite sports
starting in the 1950s. In an effort to preserve the safety and fairness of sport,
extensive programs for anti-doping and testing have become a fixture of
professional and now also recreational competitions.
The East Germans quickly recognized that androgen doping was particularly
effective in women, in whom androgen action could be raised from the low
female status to higher male realms and beyond.2 Today, every elite athlete is
subjected to rigorous testing for doping using sophisticated mass spectrometry
systems that can cost roughly $1,000,000 with certified authentic standards and
vigorous chain-of-custody documentation—testing far more technologically
advanced than most non-athletes will ever receive in their medical care.
Using these three points of reference as a framework, this Article will
logically approach a discussion of sex in sport from the endocrinologist’s
perspective. Part II will explain critical differences between male and female
biology. Part III clarifies confusion resulting from the sex versus gender
distinction. Part IV concludes that sex, and testosterone in particular, is
fundamental to the discrepancies in athletic performance between men and
women. Part V proposes solutions to defining the women’s category for the
purposes of competitive sport.
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1. See Joanna Harper, Athletic Gender, 80 LAW & CONTEMP. PROBS., no. 4, 2017, at 140–42
(pointing to early debates about who should compete in the women’s category based on the participation
of intersex and transgender athletes).
2. See Doriane Lambelet Coleman, Sex in Sport, 80 LAW & CONTEMP. PROBS., no. 4, 2017, at 72–
74 (depicting testosterone reference ranges for genetic males and females).
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II
DIFFERENCES IN MALE AND FEMALE PHYSIOLOGY
A. Human Androgen Biology
1. Sexual Differentiation
Early studies, like Alfred Jost’s pioneering work in rabbits, sought to define
the mechanisms of external genitalia formation,3 but subsequent studies
illuminated the totality of androgen biology. Jost demonstrated that a secretion
from the testis was carried through the circulation as an endocrine hormone to
cause fusion of the labia and formation of the penis. Jost reproduced this action
with exogenous testosterone (T), confirming that T was the major circulating
hormone required to cause male sexual differentiation of the external genitals.4
What Jost did not know is that an enzyme in the prostate and genital skin, 5αreductase type 2 (5R2), was required to metabolize T to dihydrotestosterone
(DHT), and it was DHT that elicited this action to form the prostate, scrotum,
and penis.5 Jean Wilson, Jim Griffin, Mike McPhaul, David Russell, and Stefan
Andersson in Dallas then went on to define the genetics and molecular biology
of 5R2 and the androgen receptor (AR, also known as NR3C4), the latter of
which mediates most if not all actions of T, DHT, and synthetic androgens. With
colleagues from around the world, they identified genetically male patients with
mutations in either the SRD5A2 gene encoding 5α-reductase type 26 or the AR
gene,7 and these seminal studies form the basis of our knowledge about androgen
biology.
2. Disorders of Androgen Biology: Androgen Insensitivity and 5R2
Deficiency
AIS and 5R2 deficiency (5R2D) afford very different phenotypes:
AIS patients appear phenotypically female at birth and feminize during
puberty.8 They develop breasts but lack facial and body hair and—critical for our
discussion—do not develop male-pattern upper-body muscular development

3. Alfred Jost, Recherches Sur la Differenciation Sexuelle de L’embryon de Lapin, 36 ARCHIVES
D’ANATOMIE MICROSCOPIQUE 151 (1947).
4. See generally Alfred Jost et al., Studies on Sex Differentiation in Mammals, 29 RECENT
PROGRESS HORMONE RES. 1 (1973); Coleman, supra note 2, at 73 (discussing the primary (reproductive)
and secondary (phenotypic) characteristics caused by testosterone).
5. See Nicholas Bruchovsky & Jean D. Wilson, The Conversion of Testosterone to 5 -Androstan-17 ol-3-one by Rat Prostate in Vivo and in Vitro, 243 J. BIOLOGICAL CHEMISTRY 2012 (1968).
6. See Marco Marcelli, A Single Nucleotide Substitution Introduces a Premature Termination Codon
into the Androgen Receptor Gene of a Patient with Receptor-Negative Androgen Resistance, 85 J.
CLINICAL INVESTIGATION 1522 (1990).
7. See Anice E. Thigpen et al., Molecular Genetics of Steroid 5a-Reductase 2 Deficiency, 90 J.
CLINICAL INVESTIGATION 799 (1992).
8. See Jean D. Wilson et al., Steroid 5a-Reductase 2 Deficiency, 14 ENDOCRINE REV. 577 (1993).
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during puberty despite a rise of circulating T that reaches the normal male range.9
In other words, the casual observer would easily identify these patients as female
sex, despite the presence of a 46,XY karyotype and testes capable of normal male
T production.
The absence of DHT generation from normal circulating T concentrations in
patients with 5R2D renders the external genitalia as phenotypically female at
birth and typically results in female sex of rearing. In contrast to AIS, however,
these patients respond normally to T production at puberty, with profound
physiologic changes including voice deepening, facial and body hair growth,
male-pattern upper-body muscle development, and male-pattern effects on the
brain.
Furthermore, the presence of the 5α-reductase type 1 isoenzyme in liver and
other tissues allows for significant virilization of the external genitalia at puberty.
Growth of the penis and descent of the testes into the (often bifid) scrotum
occurs, and some individuals with this condition make sperm and have fathered
children with assisted reproduction methods. A corollary is that the tissues are
exposed to male T concentrations during various windows in fetal and neonatal
life, which can induce genetic or epigenetic programming changes on tissues like
brain, muscle, bone, and skin. In endocrinology nosology, 5R2D individuals are
defined as undervirilized males,10 because they share all properties of normal
male physiology with the exception of the external genitalia and Wolffian duct
development. In fact, roughly half of these individuals who are not identified and
treated prior to puberty change their gender to male, a profound testament to the
potent actions of T as a hormone in multiple body tissues.
The only conditions with similar virilization and high frequency of gender
reversal during a virilizing puberty as 5R2D are 17β-hydroxysteroid
dehydrogenase type 3 (17HSD3) deficiency,11 discussed below, and partial AIS.
The enzyme 17HSD3 converts androstenedione to T in the testicular Leydig cells.
The enzyme is only expressed in the Leydig cells of the testis and is the only
human enzyme that efficiently converts androstenedione to T. Patients with
partial AIS can have a spectrum of phenotypes from normal but infertile male to
phenotypic female with some features of androgenization, and partial AIS
patients are generally the most difficult to assign into a dichotomous sex category.

9. See James E. Griffin, Androgen Resistance—The Clinical and Molecular Spectrum, 326 NEW
ENG. J. MED. 611 (1992).
10. Peter A. Lee et al., Consensus Statement on Management of Intersex Disorders, 118 PEDIATRICS
e488
(2006),
http://pediatrics.aappublications.org.proxy.lib.duke.edu/content/pediatrics/118/2/
e488.full.pdf [http://perma.cc/ET6F-TL4A].
11. See Wayne M. Geissler et al., Male Pseudohermaphroiditism Caused by Mutations of Testicular
17 -Hydroxysteroid Dehydrogenase 3, 7 NATURE GENETICS 34 (1994) (“The phenotype of 17HSD3deficient males is similar to that of 5R2D in that both have male Wolffian-duct derived internal genitalia
and external genitalia that are predominantly female in character, and in both conditions, masculinization
occurs at puberty.”).
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3. Disorders of Androgen Biology: 17β-Hydroxysteroid Dehydrogenase Type
3 Deficiency
Because 17HSD3 is only found in the testicular Leydig cells, the ovaries of
normal women and nearly all women with ovarian-derived androgen excess
states are not capable of producing sufficient T to yield normal male circulating
concentrations. Circulating concentrations of T in normal women and men show
no overlap: females typically have concentrations of less than 60 ng/dL (~2
nmol/L),12 while males have concentrations of roughly 300–1200 ng/dL (~10-40
nmol/L).13 In other words, T concentrations in normal males are five to twenty
times higher than those in normal women, and there is no overlap in the normal
ranges. Even women with severe polycystic ovary syndrome, which is the most
common condition that endocrinologists will agree are “hyperandrogenemic
women,” rarely show T concentrations >120 ng/dL (4 nmol/L).14 Because sex
hormone-binding globulin, the major binding protein for T, is typically higher in
women than in men, free and bioavailable T concentrations in normal men and
women are even more disparate than total T concentrations, for which there is
no overlap plus a large gap between normal ranges.15 For these reasons, the
International Association of Athletics Federations (IAAF) established a policy
in 2012 to use a serum T concentration <10 nmol/L to define a “female athlete.”16
This cutoff, based on substantial data (see Section II.A.4), was rather generous,
as this concentration is on the low end of T concentrations in average males and
far exceeds the T levels found in even hyperandrogenemic women. However, this
definition of female athlete is still based on sound endocrinology principles.
4. Androgens in Elite Female Athletes
Given the performance-enhancing properties of T, one might wonder if elite
female athletes possess higher circulating T than normal women. This question
was addressed at the 2011 IAAF championships in Daegu, and in fact >75% of
these elite female athletes had serum T in or close to the normal female range
and well below the normal male range.17 A subsequent study found that women
in the highest tertile of T values performed better than those in the lowest tertile

12. Richard S. Legro et al., Evidence for a Genetic Basis for Hyperandrogenemia in Polycystic Ovary
Syndrome, 95 PROC. NAT’L. ACAD. SCI. 14956 (1998).
13. Shalender Bhasin et al., Reference Ranges for Testosterone in Men Generated Using Liquid
Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young
Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts, 96 J.
CLINICAL ENDOCRINOLOGY & METABOLISM 2430 (2011).
14. Legro, supra note 12.
15. Coleman, supra note 2, at 72–74.
16. Neena A. Xavier & Janet B. McGill, Hyperandrogenism and Intersex Controversies in Women’s
Olympics, 97 J. CLINICAL ENDOCRINOLOGY & METABOLISM 3902 (2012).
17. Stéphane Bermon et al., Serum Androgen Levels in Elite Female Athletes, 99 J. CLINICAL
ENDOCRINOLOGY & METABOLISM 4328 (2014).
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for a few sports like middle-distance running.18 In both studies, however, a
disturbing number of outliers on the high end were observed,19 which cannot be
explained by normal female physiology. Some of these women are doping with
T, and other bear the endocrinology disorders that have generated the
controversy.
B. Androgens and Athletic Performance
The evidence that T is a performance-enhancing substance is irrefutable. In a
landmark study, for example, Bhasin et al. demonstrate that with or without
exercise, use of the androgen T-enanthate at 600 mg/week profoundly increases
muscle strength and size over a placebo in young healthy male athletes.20 The
dose used in this initial study might be viewed as somewhat between physiologic
and the astronomical amounts used in athletes for doping, but this same group of
investigators then showed a continuous dose-response for T and muscle
size/strength from castrate values through the female range to the male range and
beyond.21 These data strongly support the prominence of T in the genesis of
athletic advantage for men over women. Consider the following athletic
advantages in men and their origins:
1. Greater muscle size and strength: due to T, as shown in the studies of Bhasin and
colleagues.
2. Higher red blood cell mass: due to T, which induces erythropoietin expression and the
~3% higher hematocrit in men versus women.
3. Increased aggression: due to T, as shown in numerous studies of normal and castrate
men, transgender men and women, and children.
4. Lack of breasts: due to T, as T counteracts the effects of estrogen to induce breast
development, as illustrated in AIS.
5. Narrow hips: actually not due to T but rather due to lack of progesterone, which is
derived from the ovaries following ovulation. This is not a male advantage derived
from the testes but a female disadvantage derived from the ovaries.

III
SEX VERSUS GENDER
Part of the confusion generated in recent cases derives from an obfuscation
of the difference between sex and gender. “Sex” is biologically determined and
not the prerogative of the individual, while “gender” is self-determined by each
individual person. This Part will address each difference in turn.
18. Stéphane Bermon & Pierre-Yves Garnier, Serum Androgen Levels and Their Relation to
Performance in Track and Field: Mass Spectrometry Results from 2127 Observations in Male and Female
Elite Athletes, 51 BRITISH J. SPORTS MED. 1309 (2017).
19. See id.
20. Shalender Bhasin et al., The Effects of Supraphysiologic Doses of Testosterone on Muscle Size
and Strength in Normal Men, 335 NEW ENG. J. MED. 1 (1996).
21. See Thomas W. Storer et al., Testosterone Dose-Dependently Increases Maximal Voluntary
Strength and Leg Power, but Does Not Affect Fatigability or Specific Tension, 88 J. CLINICAL
ENDOCRINOLOGY & METABOLISM 1478 (2003) (showing a linear correlation of muscle mass and
strength gains with the testosterone enanthate does from 50 to 600 mg/week).

AUCHUS_CROSS REFERENCED FORMATTING FIXED (DO NOT DELETE)

132

LAW AND CONTEMPORARY PROBLEMS

2/21/2018 4:09 PM

[Vol. 80:127

A. From Chromosomal Sex to Phenotypic Sex
Our concept of sex dates back to the earliest historical records. Concepts of
sex were firmly entrenched in medical science and society at the time when
women’s sports were first introduced. Sex is an intrinsically fundamental
property that we share with other vertebrates and most animal species, and sex
forms the basis for reproduction and propagation of our species. Sex has several
components:
1. Chromosomal (Genetic) Sex
In most human beings, a 46,XY chromosomal complement (karyotype)
equates with male sex and 46,XX with female sex. “Sex reversal” occurs with the
chromosomal sex is discordant with one of the following components of sex.
2. Gonadal Sex
A 46,XY chromosome component normally drives the bipotential gonads to
develop into testes, while 46,XX affords ovarian development. Testes and ovaries
can be completely functional, completely nonfunctional, or partially functional.
For example, in Klinefelter’s syndrome (46,XXY), the testes can make normal
amounts of T during puberty but typically do not produce sperm and lose T
synthesis capacity over time. Finally, ovotestes exist in true hermaphrodites with
a spectrum of functional qualities.
3. Phenotypic Sex
At birth, only the external genitalia distinguish boys from girls
phenotypically. The internal (Müllerian and Wolffian) structures are also
sexually dimorphic, but these are not evaluated in most newborns. Because of
differences in genetics and in T exposure during fetal life, however, some priming
or influence on various organs has already occurred, which manifests later in
adolescence and adulthood. At puberty, secondary sexual characteristics
progress: breast development and pelvic widening in females versus further
growth of the penis, facial and body hair, and upper-body musculature in males.
A limited amount of contrasexual characteristics are common, like some sparse
facial hair in girls or breast budding in boys, but these changes normally stabilize
or regress as puberty progresses and the secondary sexual characteristics
expected for the chromosomal sex dominate.
Discordance of genetic and phenotypic sex have been grouped under the
terminology “Disorders of Sex Development” or “Differences in Sex
Development” (DSD),22 which replaces the previous “Intersex” or
“Pseudohermaphroditism” terms. Although many affected patients and their
families dislike these terms, this article will use the term DSD to be consistent
with current norms—but with apologies for lack of a better and accepted option
for this sensitive topic. Because androgens exert an active effect on multiple
22. Peter A. Lee et al., Global Disorders of Sex Development Update Since 2006: Perceptions,
Approach and Care, 85 HORMONE RES. PAEDIATRICS 158 (2016).
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organ systems to drive the constitutive female phenotype to the male phenotype,
DSD diagnoses are grouped based on chromosomal sex. Thus, the two largest
groups are 46,XY DSD (“undervirilized male”) and 46,XX DSD (“virilized
female”). In fact, the aforementioned Daegu study on T levels of elite female
athletes at the 2011 IAAF Championships, demonstrated that the prevalence of
DSD is seven per 1,000 (consisting of both 46,XY DSD and 46,XX DSD) among
athletes in elite women’s competition, a 140-fold increase from the general
population. This staggering increase reflects the advantage that intermediate T
values provide over the low values found in normal women. The most
conspicuous DSD in this group is those athletes with 5R2D,23 who were reared as
females and not diagnosed before entering elite competition.
4. Sex of Rearing
Parents are entrusted with the tasks of naming their babies and rearing them
in society, and for most societies, this trajectory includes a dichotomous sex of
rearing (boy/girl). As expounded below, this dichotomy is not only artificial and
inadequate for human biology but also reflects a gender of rearing, although the
choice is based primarily on the phenotypic sex and in particular the external
genitalia. When these structures are not clearly normal female or male, it is the
standard of care to determine the diagnosis leading to this condition. Not only
does the diagnosis allow for proper treatment, like corticosteroid replacement for
girls with 21-hydroxylase deficiency (21OHD), but also for the opportunity to
counsel the family about the natural history of the disorder and the statistics
about sex steroid production and sexual maturation, fertility, risk of gonadal
malignancy, and other associated conditions. The diagnosis is critical for making
treatment recommendations and framing expectations for the family in the best
interests of the child.
B. Components of Gender
In contrast to sex, gender is self-determined—only the individual can define
their gender, which is reflected in the individual’s interactions with other people
in society.24 About 0.5-1% of people in the United States report being
transgender, which means that they are living in a gender different from their
natal sex and sex of rearing. Constructions of gender and behavioral aspects of
gender as different from sex are also found in ancient cultures. In contrast, the
biological basis of gender and complexity of a gender spectrum distinct from sex
did not appear in the medical literature until well after Jost’s publications on
23. Patrick Fénichel et al., Molecular Diagnosis of 5 -Reductase Deficiency in 4 Elite Young Female
Athletes Through Hormonal Screening for Hyperandrogenism, 98 J. CLINICAL ENDOCRINOLOGY &
METABOLISM E1055 (2013), https://www.ncbi.nlm.nih.gov/pubmed/23633205 [https://perma.cc/X37Y2WPA] (follow link to full text article at Endocrine Society).
24. See Wylie C. Hembree et al., Endocrine Treatment of Transsexual Persons: An Endocrine Society
Clinical Practice Guideline, 94 J. CLINICAL ENDOCRINOLOGY & METABOLISM 3132 (2009) (“Gender
identity is used to describe a person’s fundamental sense of being a man, a woman, or of various
indeterminate and flexible genders.”).
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sexual differentiation.25 We now recognize that, just as DSD or intersex patients
exist, gender is hardly dichotomous and exists as a spectrum, with some
individuals living squarely in various intermediate genders or being gender-fluid,
not embracing either dichotomous gender, or vacillating between genders based
on situation. Sex and gender are concordant and dichotomous in most
individuals, which is consistent with a strong influence of androgens and
estrogens; however, the causality is far from complete or universal amongst
individuals. As an extreme example, there is at least one well-described case of a
patient with complete AIS (and therefore female phenotype) but firmly male
gender.26 This individual could not develop male secondary sex (genderconfirming) characteristics despite high-dose T treatment and required surgical
construction of a penis equivalent.
C. Care of Transgender Individuals
The care of transgender individuals illustrates the proper medical handling of
discordance between sex and gender. The standard of care for a male-to-female
trans woman is medical or surgical suppression of T exposure plus estrogen
replacement. The institution of gender-concordant hormone therapy with
development of gender-affirming secondary sexual characteristics eliminates
nearly 99% of the mood disturbances and tendency for personal harm that
transgender individuals suffer without proper endocrine care—with or without
gender-affirming surgeries to further enhance their phenotype.27 For a trans
woman athlete, the treatment is no different, and World Anti-Doping Agency
(WADA) policy specifies lowering T to <10 nmol/L for entering the women’s
competition. Not surprisingly, a high fraction of these athletes fail to achieve this
goal, despite access to means, given the performance enhancement of higher T.
Conversely, female-to-male trans men receive T replacement under a therapeutic
use exemption and compete against the men. Here, we find little controversy and
accusations for trans men because natal men have comparable T exposure.

25. See Joshua D. Safer & Vin Tangpricha, Out of the shadows: It Is Time to Mainstream Treatment
for Transgender Patients, 94 ENDOCRINE PRAC. 2485R (2008) (noting the lack of conventional medical
care for transgender patients).
26. Guy T’Sjoen et al., Male Gender Identity in Complete Androgen Insensitivity Syndrome, 40
ARCHIVES SEXUAL BEHAV. 635 (2011).
27. Gunter Heylens et al., Effects of Different Steps in Gender Reassignment Therapy on
Psychopathology: A Prospective Study of Persons with a Gender Identity Disorder, 11 J. SEX MED. 119
(2014).
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IV
WHAT CAN WE CONCLUDE?
Based on the principles presented here, an endocrinologist concludes the
following:
A. The women’s competition must be defined by sex, not gender
There is no logical reason to separate competitions on the self-determined
and potentially fluid parameter of gender, which provides little intrinsic
contribution to athletic performance. In contrast, this article illustrates how sex
and, in particular, differences in T production is fundamental to the discrepancies
in athletic performance typical of men and women.
B. Gender must be respected
We cannot force an athlete to change or present with a different gender just
to compete, and all athletes must be allowed to compete as themselves. This
principle will require sport and society to be more accepting of the modern
concepts of gender and the gender spectrum. We will have to become
comfortable with men (gender) competing in women’s (sex) events because that
is their biology; with women (gender) competing in the men’s (sex) events
because that is their biology; and with genderless or gender-fluid individuals in
both competitions based on their biology.
C. The diagnosis matters
We use medical science to train athletes, detect doping, and care for
transgender athletes. What would an endocrinologist do for a DSD patient who
is not an athlete? We would determine the diagnosis and recommend appropriate
therapy—that is the standard of care. The standard of care should be no different
if the patient is an elite athlete.
D. Athletes with testes, male T production and normal androgen receptors do
not belong in the women’s competition
If we are going to have a “women’s” competition, it is incomprehensible that
patients with 5RD2 are allowed to compete against athletes with normal female
T values. These athletes are male by every physiologic measure including all
those that lead to the male advantages in sport, except atypical external genitalia
and impaired fertility, which if anything would provide even greater advantages
for athletic performance. While the triaging of athletes with some conditions
might be difficult from a scientific perspective, those with 5RD2 are
unequivocally male.
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E. Athletes with ovaries but higher-than-normal T
The majority of these cases will have some form of virilizing congenital
adrenal hyperplasia like classic or nonclassic 21OHD.28 It is likely that the
prevalence of nonclassic 21OHD in elite women’s sports is far higher than the
seven per 1,000 figure for DSD. T values for untreated nonclassic 21OHD
patients are still well below the male range, whereas classic 21OHD women in
very poor control can have T values encroaching into the male range. The flip
side for women with classic 21OHD is that the more severe the condition and the
higher their T, the lower their cortisol—they have adrenal insufficiency. It is the
standard of care to replace the cortisol deficiency in classic 21OHD, and
noncompliance carries a risk of adrenal crisis.29 With at least regular physiologic
doses of hydrocortisone, their T values will not be in the male range. Enforcing
and assessing compliance will be a difficult challenge, but steroid analysis in hair
samples provides a means of long-term assessment.30 In the end, many of these
women will have higher than normal female circulating T concentrations of
adrenal origin, but other than instituting the standard of care, there is no
compelling and endocrinologically sound reason why they should not be in the
women’s competition.
F. Athletes with partial AIS
There is no straightforward answer for these athletes, who in the past were
evaluated on a case-by-case basis with liberal criteria favoring the athlete. No
alternative to this approach is apparent.
G. Transgender athletes
The current regulations, that transgender athletes should be treated with
gender-affirming hormone replacement and/or suppression to achieve T values
in the normal range for their trans-sex, are appropriate and consistent with the
standard of care. It seems unreasonable that an athlete claims to be a woman
(gender) but refuses T suppression and estrogen replacement—this behavior is
inconsistent with being transgendered.

28. See generally 21-Hydroxylase Deficiency, NAT. INST. OF HEALTH (Jan. 16, 2018),
https://ghr.nlm.nih.gov/condition/21-hydroxylase-deficiency [https://perma.cc/L3TQ-VUGW] (providing
more information about 21OHD and the congenital adrenal hyperplasias).
29. See Phyllis W. Speiser et al., Congenital Adrenal Hyperplasia Due to Steroid 21-hydroxylase
Deficiency: an Endocrine Society Clinical Practice Guideline, 95 J. CLINICAL ENDOCRINOLOGY &
METABOLISM 4133 (2010).
30. L. Manenschijn et al., A Novel Tool in the Diagnosis and Follow-Up of (Cyclic) Cushing’s
Syndrome: Measurement of Long-Term Cortisol in Scalp Hair, 97 J. CLINICAL ENDOCRINOLOGY &
METABOLISM E1836 (2012), https://www.ncbi.nlm.nih.gov/pubmed/22844063 [https://perma.cc/R2QLWUR3] (follow link for full text article at Endocrine Society).
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V
POTENTIAL SOLUTIONS
A. Eliminate the women’s competition
As an alternative to requiring everyone to compete based on their biological
sex regardless of their gender identity or how they present, we could throw up
our hands and say that there is no universally acceptable solution to the
conundrum and give up. This option would strongly discourage all but the most
competitive girls and women from seriously embracing sport and would be a
tragedy for the many female athletes who have experienced personal fulfillment
from their profession and their successes. This option would also deny countless
women competing in high school and college sports, the vast majority of whom
do not become professional athletes, an opportunity to develop valuable
teamwork and leadership traits in this setting.
B. Let anybody enter the women’s competition
This option might sound absurd. Basing participation on gender, not sex,
would open the floodgates for the many male athletes who will go to extreme
measures to win medals. Well-publicized studies have demonstrated that many
elite athletes would take a substance that would guarantee victory at high risk of
premature death.31 Posing to identify as female (temporarily) is a far easier and
safer way to gain an advantage.
C. Let the athletes decide
Although this might sound democratic, the vast majority of female athletes
will likely want stringent policing of their competition to maintain fairness from
their perspective. It is only the minority with DSD that will vote for liberalization,
and their voices will not be heard.
D. Develop an algorithm that uses medical science
Some have argued that DSD athletes in the women’s competition come from
poor countries without access to medical care and that diagnostic evaluations are
intrusive and embarrassing. These arguments are unpersuasive and inconsistent
with the care of non-athletes in these same countries. If an adolescent girl has no
menses by age sixteen or no menses and no secondary sexual characteristics by
age fourteen, a complete medical evaluation is indicated. These criteria are the
same the world over, the basic components of medical history and physical exams
are available everywhere, and basic laboratory evaluation is available in any
developed country. Can we provide athletes with expensive training facilities,
31. See, e.g., Harrison G. Pope, Adverse Health Consequences of Performance-Enhancing Drugs: An
Endocrine Society Scientific Statement, 35 ENDOCRINE REV. 341 (2014) (reviewing the high prevalence
of performance-enhancing drug use in elite and amateur athletes alike and noting that the athletes
consciously accept the increased risks of cardiovascular disease, psychiatric illness, musculoskeletal
disorders, other serious chronic health effects, and even death associated with their use).
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gear, coaching staff, and doping tests but deny them the most basic medical care?
Doing one without the other deprives the athlete of standard basic medical care
and exploits minors for the benefit of others. If we are placing the athlete’s health
first, they need to have a diagnosis and proper treatment first and foremost. If we
only care about winning medals, then we turn a blind eye to an obvious
disconnect and allow the other women to compete at an unfair disadvantage.
It is doubtful we will ever arrive at a single criterion for defining athletes who
qualify for the women’s competition. Additionally, a single unisex competition is
likely not the best solution. Instead, sport should use a basic screen first, and the
serum T measurement has performed well because of its physiologic basis. Sports
should consider lowering the 10 nmol/L cutoff to 3 nmol/L, which is closer to the
upper limit of the normal female range, if we really are serious about providing
the best medical care for the athletes because female (sex) athletes with higher
(abnormal) T levels might suffer adverse health effects without diagnosis and
proper management. Subsequent to this first screen, an algorithm based on sound
medical science should distribute athletes fairly into the appropriate
competitions. Additional testing will include biochemical and genetic testing of
steroid biosynthetic pathways, AR function, and imaging studies, which a panel
of experts should design and which will simultaneously provide the standard of
care for the athletes. Platforms to sequence of all the genes known that contribute
to DSDs on a single small blood sample are available for <$500, a pittance
compared to the budget of elite sports. Based on these subsequent results,
athletes who may not participate in the women’s competition will be identified.
Other athletes who fail the initial T screen will receive a diagnosis, standard-ofcare therapy, and clearance for the women’s competition.
These evaluations should be done at home, before any international
competition, to avoid the public displays of private information that occur when
athletes are denied proper medical care. There is no more embarrassment for an
undervirilized male to compete with a female gender in the men’s competition
than for a trans man to be in the same competition. No one will know the
difference if they start their international competition in this manner. The
embarrassment and public exposition is a consequence of accusations that arise
from attempting to conceal the obvious.

